Anadys Shareholders Challenge $230M Sale To Roche

Law360, New York (November 14, 2011, 8:33 PM EST) -- Anadys Pharmaceuticals Inc. shareholders on Monday targeted the company’s leadership along with Swiss drug giant Roche Holdings Inc. in a proposed class action accusing the two drugmakers of undervaluing Anadys stock in its planned $230 million sale to Roche.

In a complaint filed in California federal court, shareholders said they would receive $3.70 per share of Anadys common stock under the terms of the deal announced Oct. 17, even though according to Yahoo Finance, at least one analyst had set a price target of $4 per...
To view the full article, register now.




Case Information

Case Title

Christensen v. Papadopoulos et al

Case Number



California Southern

Nature of Suit



Michael M. Anello

Date Filed

November 10, 2011

Law Firms


UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.